Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein

International Journal of Cancer

Volumn 115, Issue 2, 2005, Pages 177-186

  Bäuerle, Tobias ^a   Adwan, Hassan ^a   Kiessling, Fabian ^a   Hilbig, Heidegard ^b   Armbruster, Franz P ^c   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c IMMUNDIAGNOSTIK AG   (Germany)

Author keywords

Anti BSP antibody; Bone metastasis; Bone sialoprotein (BSP); MDA MB 231 human breast cancer cell line; Nude rat model; Osteolysis

Indexed keywords

BONE SIALOPROTEIN; POLYCLONAL ANTIBODY; SIALOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL LINE MDA MB 231; CONTROLLED STUDY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RAT; X RAY;

ANIMALS; ANTIBODIES; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; GREEN FLUORESCENT PROTEINS; IMMUNOGLOBULIN G; MAMMARY NEOPLASMS, EXPERIMENTAL; OSTEOLYSIS; RATS; RATS, NUDE; SIALOGLYCOPROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 17844383523     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20840     Document Type: Article

References (31)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80: 1588-94.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
3. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999;5:3914-9.
4. Bellahcène A, Menard S, Bufalino R, Moreau L, Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 1996;69:350-3.
5. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001;280:460-5.
6. Ganss B, Kim RH, Sodek J. Bone sialoprotein. Crit Rev Oral Biol Med 1999;10:79-98.
7. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH. Animal models of bone metastasis. Cancer 2003;97:748-57.
8. Hebel R, Stromberg MW. Anatomy and embryology of the laboratory rat, 2nd ed. Wörthersee: BioMed Verlag, 1986.
9. Price JE. Metastasis from human breast cancer cell lines. Br Cancer Res Treat 1996;39:93-102.
10. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999;17:163-7.
11. Peyruchaud O, Winding B, Pécheur I, Serre CM, Delmas P, Clézardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-34.
12. Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001;16:1486-95.
13. Kjønniksen I, Winderen M, Bruland Ø, Fodstat Ø. Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. Cancer Res 1994;54:1715-9.
14. Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumor growth. Int J Cancer 2003;107:468-77.
15. Paulus MJ, Gleason SS, Kennel SJ, Hunsicker PR, Johnson DK. High resolution X-ray computed tomography: an emerging tool for small animal cancer research. Neoplasia 2000;2:62-70.
16. Mastro AM, Gay CV, Welch DR. The skeleton as a unique environment for breast cancer cells. Clin Exp Metastasis 2003;20:275-84.
17. Bellahcène A, Antoine N, Clausse N, Tagliabue E, Fisher LW, Kerr JM, Jarès P, Castronovo V. Detection of bone sialoprotein in human breast cancer tissue and cell lines at both protein and messenger ribounucleic acid levels. Lab Invest 1996;75:203-10.
18. Bellahcène A, Castronovo V. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bull Cancer 1997;84; 17-24.
19. Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, Ganss B, Cheifetz S. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 2000;18:253-60.
20. Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegård D, Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 2003;20:437-44.
21. Waltregny D, Bellahcène A, De Levai X, Florkin B, Weidle U, Castronovo V. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 2000;15:834-43.
22. Zhang JH, Tang J, Wang J, Ma W, Zheng W, Yoneda T, Chen J. Overexpression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol 2003;23:1043-8.
23. Chen J, Rodriguez JA, Barnett B, Hashimoto N, Tang J, Yoneda T. Bone sialoprotein promotes tumor cell migration in both in vitro and in vivo models. Connect Tissue Res 2003;44:279-84.
24. Adwan H, Bäuerle TJ, Berger MR. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 2004;11:109-20.
25. Sung V, Stubbs JT 3rd, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 1998;176:482-94.
26. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N, Clézardin P. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-8.
27. Pilch J, Habermann R, Felding-Habermann B. Unique ability of integrin alpha(v)beta3 to support tumor cell arrest under dynamic flow conditions. J Biol Chem 2002;277:21930-8.
28. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003;20:203-13.
29. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin-binding ligand N-linked glycoproteins (SIBLINGS) bind and activate specific matrix metalloproteinases. FASEB J 2004;18:734-6.
30. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107.
31. Adwan H, Bäuerle T, Najajreh Y, Elazer V, Golomb G, Berger MR. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 2004;24:1235-44.